Asia Pacific Cancer Vaccines Market Key Players and Forecast by 2027

The Asia Pacific cancer vaccines market was valued at US$ 861.55 million in 2019 and is projected to reach US$ 3,131.09 million by 2027; it is expected to grow at a CAGR of 17.9% during the forecast period.

The growth of the Asia Pacific Cancer Vaccines market is mainly attributed to the growing prevalence of cancer and initiatives taken by global health organization.

In Asia Pacific, China is the largest market for cancer vaccines market. The growth of the market is primarily attributed to the growing biotechnology market, increasing developments by the market players, and favorable regulatory policies. The excessive population in China coupled with the rise of cancer prevalence is majorly driving the growth of the cancer vaccines in China and making it a prime market in the Asia Pacific region.

In addition, in the last few years, the companies in china are undergoing collaborations, partnerships and mergers to advance the cancer vaccines technology. For instance, Researchers from Queen Mary University of London and Zhengzhou University collaborated to develop a personalised vaccine system that could ultimately delay the onset of pancreatic cancer. The research was funded by the Chinese Ministry of Science and Technology and Zhengzhou University and was published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

China Cancer Vaccines Market Revenue and Forecast to 2027 (US$ Million)

ASIA PACIFIC CANCER VACCINES – MARKET SEGMENTATION

By Technology

• Dendritic Cells Cancer Vaccines
• Recombinant Cancer Vaccines
• Antigen Cancer Vaccines
• Whole Cell Cancer Vaccines
• Viral Vector Cancer Vaccines

By Type

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccine

By Indication

• Cervical Cancer
• Prostate Cancer
• Other Indications

By End Use

• Pediatrics
• Adults

By Country

• US
• Canada
• Mexico

Company Profiles

• AstraZeneca
• GlaxoSmithKline plc.
• Aduro Biotech Inc
• Pfizer Inc.
• Sanofi
• Bristol-Myers Squibb
• Moderna, Inc.
• OncBioMune Pharmaceuticals Inc.
• MaxiVAX
• Nouscom

Asia Pacific Cancer Vaccines Report Scope